Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Exagen (XGN) Cash from Financing Activities (2018 - 2025)

Exagen (XGN) has disclosed Cash from Financing Activities for 8 consecutive years, with -$384000.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Financing Activities fell 77.78% year-over-year to -$384000.0, compared with a TTM value of $24.4 million through Dec 2025, up 3785.52%, and an annual FY2025 reading of $24.4 million, up 3785.52% over the prior year.
  • Cash from Financing Activities was -$384000.0 for Q4 2025 at Exagen, down from $2.9 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $65.1 million in Q1 2021 and bottomed at -$10.2 million in Q2 2023.
  • Average Cash from Financing Activities over 5 years is $3.9 million, with a median of -$114500.0 recorded in 2023.
  • The sharpest move saw Cash from Financing Activities surged 127709.8% in 2021, then plummeted 3779.55% in 2023.
  • Year by year, Cash from Financing Activities stood at -$213000.0 in 2021, then grew by 18.78% to -$173000.0 in 2022, then fell by 27.17% to -$220000.0 in 2023, then grew by 1.82% to -$216000.0 in 2024, then crashed by 77.78% to -$384000.0 in 2025.
  • Business Quant data shows Cash from Financing Activities for XGN at -$384000.0 in Q4 2025, $2.9 million in Q3 2025, and $21.9 million in Q2 2025.